Upon activation, they can enhance the proliferation and activation of engineered T cells by promoting T cell receptor (TCR) and cytokine-driven JAK-STAT signaling ( ex vivo , and then reinfused into the patient ( Kymriah, a CD19-specific CAR-T product, was the first to be approved on August 31, 2017, for treating patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia (B-ALL) ( Yescarta, a second CD19-specific CAR-T product, was approved on October 18, 2017, for adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and transformed follicular lymphoma (TFL), after two or more lines of systemic therapy ( Tecartus, a third anti-CD19 CAR-T product, was approved for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL) patients on July 24, 2020 ( Breyanzi, another CD19-specific CAR-T product, was approved on February 5, 2021
direct delivery into the bloodstream , ensuring maximum absorption, while oral supplements can be limited by digestion and metabolism
Consortia must also include at least one funded patient partner, brought in through a PAO or another organised patient group, and must secure access to a qualified multinational Clinical Trial Management Organisation (CTMO)
65: Elsevier
